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Signaling via the p75 
neurotrophin receptor facilitates 
amyloid‑β‑induced dendritic spine 
pathology
Abhisarika patnaik1, Marta Zagrebelsky1, Martin Korte1,2 & Andreas Holz2*
Synapse and dendritic spine loss induced by amyloid-β oligomers is one of the main hallmarks of the 
early phases of Alzheimer’s disease (AD) and is directly correlated with the cognitive decline typical of 
this pathology. The p75 neurotrophin receptor  (p75ntR) binds amyloid-β oligomers in the nM range. 
While it was shown that µM concentrations of amyloid-β mediate cell death, the role and intracellular 
signaling of  p75ntR for dendritic spine pathology induced by sublethal concentrations of amyloid-β 
has not been analyzed. We describe here  p75ntR as a crucial binding partner in mediating effects of 
soluble amyloid-β oligomers on dendritic spine density and structure in non-apoptotic hippocampal 
neurons. Removing or over-expressing  p75ntR in neurons rescues or exacerbates the typical loss of 
dendritic spines and their structural alterations observed upon treatment with nM concentrations of 
amyloid-β oligomers. Moreover, we show that binding of amyloid-β oligomers to  p75ntR activates 
the RhoA/RocK signaling cascade resulting in the fast stabilization of the actin spinoskeleton. our 
results describe a role for  p75ntR and downstream signaling events triggered by binding of amyloid-β 
oligomers and causing dendritic spine pathology. these observations further our understanding of the 
molecular mechanisms underlying one of the main early neuropathological hallmarks of AD.
The p75 neurotrophin receptor  (p75NTR; also known as Nerve Growth Factor Receptor, NGFR) is a member of 
the tumor necrosis factor receptor superfamily that is capable to bind all neurotrophins with similar affinities in 
the nano-molar  scale1. Originally, this transmembrane protein was described to act in concert with the frequently 
co-expressed Trk receptor family of tyrosine kinases to balance neuronal survival and death, in particular during 
 development2. However,  p75NTR itself has also been found to serve multiple, in parts opposing cellular functions 
within the CNS and in the  periphery1. For instance, triggered by neurotrophins and their proforms, the  p75NTR 
signaling molecule can induce apoptosis in neural  cells3, but is also able to promote cell survival in different 
cellular  settings4,5. Moreover,  p75NTR has been implicated in cell cycle  control6,7, axonal  outgrowth8, synaptic 
transmission as well as functional and structural  plasticity9–11.
Interestingly,  p75NTR serves as a receptor for amyloid-β, a major component of the plaques found in the 
brain of Alzheimer’s disease (AD)  patients12. The extracellular domain of  p75NTR is able to bind Aβ-peptides at 
effective concentrations similar to those of  NGF13. The interaction between  p75NTR and amyloid-β in the µM 
range has been shown to cause cytotoxicity and apoptosis in different cell  types12,14, including hippocampal 
 neurons15,16. In addition, also Tau pathology might be influenced by  p75NTR17,18. These studies are in agreement 
with early findings showing that either the overexpression or the induced upregulation of the  p75NTR receptor 
enhanced amyloid-β-triggered cytotoxic effects on neuronal  cells19. However,  p75NTR also has been reported to 
confer neuroprotective capabilities against the damaging actions of soluble Aβ  oligomers20,21 as  p75NTR/Aβ1–42 
interactions triggered rapid neurite  formation22.
Additional findings link  p75NTR with neurodegeneration and AD. For instance, while the expression of  p75NTR 
diminishes in the CNS once development is completed, adult cholinergic neurons of the basal forebrain, which 
are among the first CNS neurons affected in  AD23, persistently express high levels of  p75NTR24. Moreover,  p75NTR 
expression is upregulated in neurons of the aged and AD-afflicted  cortex25.
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While most reported studies analyzed neural apoptosis mediated by the binding of amyloid-β to  p75NTR, we 
sought to examine the acute effects triggered by  p75NTR/amyloid-β interactions with a specific focus on synapses 
and dendritic spine pathology. Indeed, amyloid-β oligomers are binding preferentially to synapses at dendritic 
 spines26 and rapidly induce dendritic spine  loss27. The loss of dendritic spines observed in AD is intimately 
linked with synaptic dysfunction and loss of memory and  cognition28. Furthermore,  p75NTR has been shown to 
negatively modulate dendrite complexity and dendritic spine density in hippocampal  neurons9.
We took advantage of a series of loss- and gain-of-function approaches for  p75NTR including a knockout 
(ko) mouse strain having a complete  p75NTR  deletion29 and its over-expression. Comparing mature primary 
hippocampal neurons from wild type controls with those from  p75NTR ko mice we observe an almost complete 
protection from Aβ1–42-induced changes in dendritic spine number and morphology in knockout animals. On 
the contrary, gain-of-function for  p75NTR exacerbates the spine alterations seen in wild type neurons. Analyzing 
the downstream-signaling events triggered by the amyloid-β/p75NTR interaction, we implicate RhoA/ROCK 
activation as an important factor in causing actin cytoskeleton stabilization presumably mediating the morpho-
logical alterations at dendritic spines.
Results
The genetic ablation of the p75 neurotrophin receptor protects hippocampal neurons against 
Aβ1–42 mediated spine pathology. It is well established that the long-term treatment of both cell lines 
and primary neurons with amyloid-β (Aβ1–42) oligomers in the µM range results in neuronal degeneration 
and cell death per  apoptosis30. These effects have been shown to depend on the specific binding of the Aβ1–42 
oligomers to the  p75NTR  receptor14,16 and the activation of downstream signaling. Here we were primarily inter-
ested in analyzing the sublethal effects of acute Aβ1–42/p75NTR interactions in the nM range. By this means we 
analyzed possible intracellular signaling events which might lead to dendritic spine alterations. Dendritic spine 
pathology is one of the principal symptoms of Aβ1–42 accumulation in early AD.
Initially, f-eGFP expressing DIV14 primary hippocampal neurons, obtained from C57BL/6 wild type animals 
were incubated with increasing amounts of Aβ1–42 in the nM range and their impact on dendritic spine density 
and morphology was analyzed after six hours (Fig. 1A–D). This time point has been chosen since it has been 
reported previously to cause significant dendritic alterations upon treatment with Aβ  oligomers31. While incu-
bations with 10 and 50 nM Aβ1–42 oligomers resulted in no or only a mild reduction in dendritic spine density 
when compared to the control condition, application of 100 nM Aβ1–42 oligomers resulted in a significantly lower 
dendritic spine density (Fig. 1B). This decrease was even stronger upon application of 500 nM Aβ1–42 oligomers 
(Fig. 1B), indicating a dose-dependent effect. The decrease in spine density was associated with structural changes 
in the remaining dendritic spines. Particularly, a significant increase in dendritic spine length (Fig. 1C) and a 
significant decrease in the spine head width (Fig. 1D) was observed using the higher concentrations of Aβ1–42 
oligomers (100–500 nM). Interestingly, while the application of 50 nM Aβ1–42 oligomers did not alter dendritic 
spine structure, 10 nM Aβ1–42 oligomers caused a small increase in the spine head width (Fig. 1D) that coincided 
with a decrease in the length (Fig. 1C) of treated spines.
Importantly, a 6-h treatment with 500 nM Aβ1–42 oligomers did not cause any detectable apoptosis in neu-
rons (Fig. 2, Supplementary Fig. S1). In general, only very few activated Caspase-3 (Fig. 2) and TUNEL-positive 
(Fig. S1) neurons (defined by their MAP2 expression; Figs. 2A and S1A) were observed in the analyzed primary 
hippocampal cultures and there were no differences in apoptotic neurons between vehicle- and Aβ1–42-treated 
neuronal cultures (Figs. 2B and S1B–D).
In summary, these data demonstrate that a 6-h treatment of wild type mature primary hippocampal neurons 
with Aβ1–42 oligomers causes a reduction in dendritic spine density associated with a switch toward an immature 
phenotype of the remaining dendritic spines. These observations are in line with previous  reports27. Interestingly, 
low concentrations of Aβ1–42 (10 nM) seem to promote dendritic spine maturation. It should be noted that a 
rather brief incubation for 15 min of primary hippocampal neurons with amyloid-β oligomers had no effect on 
both the density and the morphology of dendritic spines (Supplementary Fig. S2).
Intriguingly, when increasing amounts of Aβ1–42 oligomers were added to f-eGFP expressing mature primary 
hippocampal neurons obtained from  p75NTRexon-IV knockout  mice29, the alterations observed in wild type mice 
were completely prevented (Fig. 1A, E–G, Supplementary Fig. S2). In fact, when compared to the control condi-
tions even at the highest concentration of Aβ1–42 oligomers tested (i.e. 500 nM) no changes in dendritic spine 
density (Fig. 1E) as well as in dendritic spine length (Fig. 1F) and head width (Fig. 1G) were detected. Consid-
ering that  p75NTR is not the only reported neuronal receptor serving as a ligand for amyloid-β32, these results 
indicate that it must play a major role in triggering Aβ1–42-induced alterations in dendritic spine morphology.
Overexpression of  p75ntR leads to higher sensitivity of primary hippocampal neurons to the 
deleterious effects of Aβ1–42 on dendritic spines. Next, we evaluated the impact of the neuronal over-
expression of full-length variants of  p75NTR on mediating amyloid-β induced dendritic changes. For this pur-
pose, primary hippocampal neurons were either transfected with an expression vector encoding the rat  p75NTR 
together with f-eGFP to visualize the neurons (Fig. 3A)9 or with the eGFP-tagged human  p75NTR (Fig. 3B)33. 
As a control, neuronal cultures were transfected with the f-eGFP-expressing plasmid alone. Subsequently, the 
neuronal cultures were treated on DIV14 with increasing concentrations of Aβ1–42 oligomers for 6 h and the 
spine density and morphology of individual neurons were evaluated. Since the sole over-expression of  p75NTR 
causes alterations in dendritic spine  morphology9, the results obtained from amyloid-β treated dendrites of 
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Similar to the results described above in Fig. 1, the neurons that expressed f-eGFP alone and were treated 
with Aβ1–42 oligomers showed a dose-dependent decrease in dendritic spine density when compared to vehicle 
controls (Fig. 3C). Likewise, we observed an increase in spine length (Fig. 3D) as well as a decrease in spine head 
width (Fig. 3E) in those neurons that had received amyloid-β oligomers. Remarkably, the overexpression of both 
human and rodent  p75NTR isoforms led to a significantly stronger decrease in the density of dendritic spines 
after both 100 and 500 nM amyloid-β treatment when compared to f-eGFP-expressing control neurons, which 
had been treated with identical amounts of amyloid-β oligomers (Fig. 3C). The application of Aβ1–42 oligomers, 
however, had no comparable effects on the length (Fig. 3D) nor on the head width (Fig. 3E) of the remaining 
dendritic spines of  p75NTR overexpressing neurons.
Figure 1.  The ablation of  p75NTR rescues acute amyloid-β induced changes in dendritic spine morphology. 
Primary hippocampal neurons from wild type (A, B–D) and  p75NTR ko (A, E–G) mice were incubated with 
vehicle (PBS; 0) or with 10, 50, 100, or 500 nM Aβ1–42 oligomers for 6 h. (A) shows representative images as 
maximum intensity projections of dendrites of f-GFP+ expressing neurons, which were co-stained with MAP2 
to visualize the entire dendritic network. An evaluation of the spine density (B, E), spine length (C, F), and spine 
head width (D, G) is shown in the graphs where dendritic segments with a length of ≥ 100 µm were used for 
analysis for wild type and  p75NTR ko neurons. Columns represent mean values + SEM and dots mark data points 
of individual neurons. The number of evaluated cells, obtained from three independent sets of experiments, is 
given in each column of the graphs. Statistical significance was tested using a one-way ANOVA with Sidak post-
test. ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Scale bar: 20 µm.
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The localization of amyloid-β at dendritic spines is dependent on the levels of  p75ntR. Our 
data suggest that  p75NTR is an important membrane component mediating the effects of Aβ1–42 oligomers on 
dendritic spines. Hence, we sought to evaluate in more detail the direct interactions of amyloid-β with den-
dritic spines depending on the  p75NTR expression levels. Initially, we compared the colocalization of amyloid-
β-immunoreactive puncta with dendritic spine heads in f-eGFP expressing wild type and  p75NTR knockout pri-
mary hippocampal neurons after a short-term incubation of 15 min with increasing concentrations of Aβ1–42 
oligomers (Fig.  4A,B). We observed that both in wild type and  p75NTR ko neurons the number of amyloid-
β-immunoreactive puncta associated with dendritic spines increased in a concentration-dependent manner. 
In addition, the percent of spines colocalized with amyloid-β-immunoreactive puncta in wild type neurons 
was consistently higher when compared to  p75NTR ko neurons (Fig. 4B). At the highest concentration of Aβ1–42 
oligomers analyzed (i.e. 500 nM Aβ1–42), 23.1 ± 2.4% (mean ± SEM; n = 23) of wild type dendritic spines were 
associated with amyloid-β-immunoreactive puncta, whereas in contrast spines from  p75NTR ko neurons showed 
a colocalization ratio of only 6.9 ± 1.1% (mean ± SEM; n = 24), a difference that was statistically highly significant 
(p < 0.0001).
In order to analyze more long-term effects of the interaction of Aβ1–42 oligomers with dendritic spines, we 
extended the Aβ1–42 incubation times to 6 h (Fig. 4C). At this time point, the differences in the relative amounts 
of spine-associated amyloid-β-immunoreactive puncta between wild type and  p75NTR ko neurons were less 
pronounced and did not reach any longer statistical significance (27.7 ± 2.3%, n = 28 vs. 21.2 ± 1.5%, n = 33, 
respectively, for treatment with 500 nM Aβ1–42; mean ± SEM, p = 0.08, Fig. 4C). The overexpression of rodent or 
human  p75NTR in neurons, however, significantly augmented the amount of amyloid-β-immunoreactive puncta 
localized at dendritic spines (Fig. 4C) when compared to wild type. Interestingly, the overexpression of the 
human  p75NTR resulted in a higher colocalization than the rodent one (Fig. 4C). This data emphasizes that  p75NTR 
serves as an important receptor for amyloid-β binding, in particular for the initial phases of amyloid-β/receptor 
interactions. However, it also confirms the notion that other amyloid-β receptors are located at dendritic spines 
of hippocampal neurons.
Mechanistic insight: amyloid-β induced activation of RhoA requires presence of  p75ntR. We 
documented amyloid-β-induced alterations of dendritic spines of primary neurons that could be rescued by the 
removal of  p75NTR. Moreover, we show that Aβ1–42 is localized at dendritic spines and that the levels of neuronal 
 p75NTR expression influence strongly the association of amyloid-β with spines. Therefore, we next searched for 
a potential downstream mechanism explaining the amyloid-β/p75NTR mediated changes in spine morphology. 
Since it has been reported that  p75NTR is capable to activate  RhoA8 at a fast time  scale34 and RhoA signal-
ing is implicated in remodeling the actin cytoskeleton, including the modulation of spine  dynamics35,36 within 
 minutes37, we hypothesized that Aβ1–42/p75NTR interactions trigger the activation of the RhoA/ROCK pathway, 
ultimately leading to changes in the actin composition and dendritic spine architecture.
We first analyzed if amyloid-β is capable to activate RhoA in murine primary hippocampal cultures and 
whether this cellular event is influenced by the presence of  p75NTR. Hence, we added Aβ1–42 oligomers for 
10 min to primary neurons from wild type and from  p75NTR ko cultures and performed an ELISA-based assay 
Figure 2.  Treatment with nM amyloid-β does not induce apoptosis in hippocampal neurons. (A) Shows 
representative images of primary hippocampal cultures from wild type that were treated with vehicle (CTRL, 
top panels) or with 500 nM Aβ1–42 oligomers (bottom panels) for 6 h and were stained for MAP2 (green) and 
cleaved caspase-3 (red). A DAPI staining visualizes nuclei (blue). Arrows indicate MAP2-expressing neurons 
positive for the cleaved caspase-3 (Scale bar: 100 µm). The inserts A1 and A2 show in detail two neuronal cell 
bodies positive for the cleaved caspase-3 (Scale bar: 20 µm). (B) The graph compares the percent of neurons 
positive for the cleaved caspase-3 in vehicle-treated (dark blue) and Aβ1–42 oligomers treated (light blue) wild 
type hippocampal cultures. Columns represent mean values + SEM. The number of evaluated fields, obtained 
from two coverslips of two independent sets of experiments, is given within each column of the graphs. 
Statistical significance was tested using a Student’s t-test (p = 0.8903).
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to determine the activation state of RhoA molecules, i.e. its GTP-bound  form38. Intriguingly, we observed a sig-
nificant activation of RhoA for wild type hippocampal cultures upon treatment with Aβ1–42 oligomers (Fig. 5). 
Interestingly, the RhoA activation level in vehicle-treated  p75NTR ko cultures was lower, albeit not significantly 
(p = 0.0961, Two-way ANOVA with Tukey post-test), than in vehicle-treated wild type neurons (Fig. 5). Impor-
tantly, the application of Aβ1–42 oligomers to  p75NTR-deficient neuronal cultures did not result in any measurable 
RhoA activation (Fig. 5). This data indicate that Aβ1–42 oligomers are able to cause the  p75NTR-dependent activa-
tion of RhoA in primary hippocampal cultures.
The inhibition of  p75ntR‑mediated RhoA/RocK signaling rescues amyloid‑induced changes 
in dendritic spine morphology. Next, we utilized inhibitors known to prevent the activation of  p75NTR 
downstream signaling to RhoA to test the hypothesis that  p75NTR is able to mediate the effect of Aβ1–42 oligomers 
on dendritic spine structure by directly controlling the activation of the RhoA. The TAT-Pep5 fusion peptide 
has been described to be able to enter the cell and to specifically inhibit  p75NTR-mediated RhoA  activation39. 
In addition, we also employed the Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor 
Y-2763240. Upon a 6-h treatment with 500 nM Aβ1–42 oligomers, f-eGFP expressing primary hippocampal neu-
rons showed a significant decrease in dendritic spine density (Fig. 6A,B) associated with significant morphologi-
cal changes in spine length (Fig. 6A,C) and spine head width (Fig. 6A,D), similar to the results described above 
(see Fig. 1). Interestingly, a pretreatment of the neuronal cultures either with the TAT-Pep5 peptide, inhibiting 
the  p75NTR-mediated RhoA activation, or with the pan-ROCK inhibitor Y-27632 both protected hippocampal 
neurons from the Aβ1–42 oligomer-induced alterations in dendritic spine number and structure (Fig. 6A–D). 
Specifically, preventing the  p75NTR mediated activation of RhoA or inhibiting ROCK blocked significant changes 
Figure 3.  Overexpression of the  p75NTR signaling receptor aggravates the dendritic spine loss triggered 
by amyloid-β1–42 oligomers. Primary hippocampal cultures were either transfected with expression vectors 
encoding f-eGFP (eGFP, C–E) or with a fusion protein of human full-length  p75NTR with eGFP (human 
 p75NTR-eGFP, B, C–E), or alternatively were co-transfected with plasmids encoding f-eGFP and full-length 
rat  p75NTR (rat  p75NTR, A, C–E). (A) demonstrates the co-expression of f-eGFP (green, left panel) with 
immunohistochemically-labeled rat  p75NTR (red, middle panel) in a dendritic segment of a transfected 
neuron. Note that  p75NTR overexpression is not noticeable in all dendritic spines (arrows in the right, ‘merged’ 
panel). (B) shows the overexpression of the human  p75NTR variant that is directly fused to eGFP. Subsequent 
to all transfections, the neurons (DIV14) either received vehicle (CTRL) or were incubated with increasing 
concentrations of Aβ1–42 oligomers as indicated for 6 h (C–E). Amyloid-β treated samples of each experimental 
group were normalized to the corresponding controls, which were treated with equivalent volumes of vehicle 
as control. The evaluation of dendritic spine density (C), spine length (D), and spine head width (E) is shown 
in the graphs. The data are presented as mean + SEM. One-way ANOVA with Sidak post-test was used to 
compare the means of the control (eGFP) to  p75NTR overexpression groups for each Aβ1–42-treatment. P values 
as indicated or **** = p < 0.0001. The number of analyzed neurons resulting from three independent experiments 
is given for each data column. Scale bar: 5 µm.
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in either dendritic spine density (Fig. 6A,B), spine elongation (Fig. 6A,C), or spine head diameter (Fig. 6A,D) 
when compared to the corresponding controls.
Involvement of  p75ntR amyloid-β induced changes in the actin filament. Above we analyzed the 
contribution of the RhoA/ROCK pathway in transducing the interaction of Aβ1–42 oligomers with the  p75NTR 
receptor. Finally, we examined whether these  p75NTR mediated signaling events influenced the actin cytoskeletal 
network in dendritic spines.
First, we used phalloidin staining to compare the levels of F-actin within dendritic spines from individual 
wild type and  p75NTR knockout animals (Fig. 7A,B). Under basal conditions, only low levels of F-actin could be 
identified in the dendritic spines of both genotypes (Fig. 7A,B).
Next, we sought to assess the effect of the application of Aβ1–42 oligomers on the F-actin levels within spines 
by incubating f-eGFP expressing primary hippocampal neurons with 500 nM Aβ1–42 for 10 min. We observed 
Figure 4.  Colocalization of amyloid-β to dendritic spines is dependent on the expression levels of  p75NTR. (A) 
gives a representative example of the distribution of amyloid-β immunoreactive puncta (red) at a dendritic 
segment of f-eGFP-transfected neurons (green), which either were obtained from wild type (left) or  p75NTR 
ko (middle) mice, or were co-transfected with an expression vector encoding rodent  p75NTR (right). Arrows 
indicate dendritic spines colocalized with amyloid-β-immunoreactive puncta. The red puncta that did not 
colocalize with dendritic f-eGFP labeled spines stem from out-of-focus amyloid-β oligomers binding to 
neuronal processes of non-transfected neurons. Treatment of the primary hippocampal cultures (DIV 14) with 
Aβ1–42 oligomers was for 15 min. The graphs illustrate the quantification of the proportion of amyloid-β-positive 
dendritic spines of neurons, which received vehicle or increasing amounts of Aβ1–42 oligomers for 15 min 
(B) or 6 h (C). Hippocampal neurons were wild type (B, C; blue), had knockout for  p75NTR (B, C; green), or 
overexpressed human (C, red) or rat  p75NTR (C, orange). Each bar shows the mean values + SEM. To compare 
the means from wild type and  p75NTR knockout neurons in B, One-way ANOVA with Sidak post-test was used. 
In C, a Two-way ANOVA with Tukey post-test was applied. The numbers at the bottom of each column give the 
amount of analyzed neurons, which were obtained from three independent experiments. Statistical significances 
as indicated or **** = p < 0.0001; ns = not significant. Scale bar in (A) is equivalent to 5 µm.
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that this brief treatment caused a significant increase in the F-actin intensity specifically in those dendritic 
spines colocalized with Aβ1–42 immunoreactive puncta (Fig. 7C,E). Importantly, the levels of F-actin within 
dendritic spines were strictly dependent on the presence of Aβ1–42 since dendritic spines of the same neurons 
lacking Aβ1–42 immunoreactive puncta did not show any significant increase in F-actin (Fig. 7C,E). Interestingly, 
in  p75NTR-deficient neurons the F-actin intensity within amyloid-β+ dendritic spines increased only slightly, 
but not significantly, when compared to the control condition (p = 0.08, Fig. 7D,E). Furthermore, the F-actin 
intensity in spines of  p75NTR ko neurons was clearly, albeit also not significantly, lower than in wild type cells 
(p = 0.09; Fig. 7E).
In summary, our data suggest that the interaction of Aβ1–42 oligomers with the  p75NTR triggers an intracel-
lular RhoA/ROCK signaling cascade that likely leads to alterations in actin polymerization in dendritic spines of 
primary hippocampal neurons. The ablation of  p75NTR largely prevents the activation of these  p75NTR mediated 
intracellular signaling events of the RhoA/ROCK pathway and the actin polymerization, thereby protecting 
 p75NTR ko neurons from the Aβ1–42-induced dendritic spine pathology.
Discussion
Understanding the role of oligomeric Aβ1–42 in inducing the dendritic spine pathology most likely causing 
the symptoms typical of the initial phases of AD requires to elucidate the signaling mechanisms activated by 
amyloid-β at synapses. While Aβ has been shown to bind to several membrane receptors, our results provide 
strong evidence for a crucial role of  p75NTR signaling in the Aβ1–42-induced structural alterations at synapses 
directly. In this study, we show that  p75NTR signaling is required for the dendritic spine loss and structural 
changes observed in mature primary hippocampal neurons upon application of increasing nM concentrations 
of Aβ1–42 oligomers. Moreover, we show that the activation of  p75NTR upon Aβ1–42 oligomer treatment results in 
a RhoA-ROCK-mediated stabilization of the actin spinoskeleton followed by spine loss as well as shrinking and 
elongation of the remaining spines.
While Aβ plaques are the typical hallmark of the advanced phases of AD it is now rather believed that it is the 
soluble Aβ1–42 oligomers that, binding with high affinity at synaptic sites, impair the function and structure of syn-
apses at the onset of the  disease41. Soluble Aβ1–42 oligomers are found in several AD mouse models and in human 
patients and their levels correlate with synaptic  loss42, impairment of synaptic transmission and  plasticity43,44 as 
well as AD-associated cognitive  decline45,46. While in vitro higher concentrations of Aβ oligomers, in the µM 
range, are well known to induce neuronal death by  apoptosis30,47,48, lower pM to nM Aβ concentrations have 
been shown to bidirectionally regulate activity-dependent synaptic  plasticity49. However, only few studies so far 
addressed the sublethal Aβ effects on the architecture of neurons. Here we show that Aβ1–42 oligomers accumulate 
at dendritic spines of wild type hippocampal neurons within minutes and reside there up to hours after starting 
the treatment. Likewise, synthetic Aβ oligomers were previously shown to specifically accumulate at excita-
tory synapses in an activity-dependent  manner31,50,51. Since most of the excitatory synapses in the mammalian 
brain form contacts onto dendritic spines these previous observations are in good agreement with our results. 
Moreover, we observed a concentration-dependent decrease in dendritic spine density in primary hippocampal 
neurons treated with synthetic Aβ1–42 oligomers. In fact, dendritic spine loss is one of the main hallmarks of 
 AD52–55. In addition, we observed that the remaining dendritic spines show an increase in their length and a 
decrease in the head width, typical of an immature phenotype. These findings are supported by results of previ-
ous studies showing a rapid decrease in the density of both synaptic structures and dendritic spine in response 
to both naturally secreted and synthetic Aβ  peptides27,31,51,56 and identify a strong and reliable phenotype to be 
Figure 5.  Interactions of Aβ1–42 oligomers with the  p75NTR transmembrane receptor causes activation of 
cytoplasmic RhoA. The treatment of primary hippocampal neurons (DIV14) with vehicle vs. 500 nM Aβ1–42 
oligomers for 10 min results in a significant activation of the small GTPase RhoA in  p75NTR competent cells. 
In contrast, neurons obtained from  p75NTR ko mice did not show a comparable activation of RhoA in response 
to an equivalent amyloid-β treatment. RhoA activity was determined in neuronal preparations by G-ELISA. 
Columns values are mean + SEM. Statistical analysis was performed using a Two-way ANOVA assay with Tukey 
post-test. P values are specified. The number of experimental repetitions is given in the graphs.
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used to analyze the downstream signaling involved in this processes. Importantly, our results show that under 
the experimental conditions used in this study, the number of cleaved caspase-3 and TUNEL-positive neurons 
in hippocampal cultures is extremely low and especially it is not increased upon a 6 h treatment with 500 nM 
Aβ1–42 oligomers. This observation strongly indicates that the dendritic spine phenotype observed here is not 
the consequence of Aβ-induced apoptosis but rather of a sublethal effect of Aβ oligomers.
Several surface receptors have been identified to bind Aβ oligomers at the neuronal surface and trigger a 
series of intracellular signaling pathways negatively affecting their survival and  function57. However, the role of 
several of these receptors is still controversial and their downstream signaling mediating the synaptic effects of 
Aβ1–42 oligomers are largely unknown. We show here strong evidence for a role of the  p75NTR in mediating the 
effects of Aβ1–42 oligomers on the neuronal architecture in a specific manner, since a complete  p75NTR knock-
out significantly reduces the accumulation of Aβ1–42 to dendritic spines and completely rescues spine loss and 
changes in spine architecture. Conversely,  p75NTR overexpression strengthens both Aβ1–42 accumulation and 
spine loss without exacerbating the changes in dendritic spine architecture observed under control conditions. 
A link between  p75NTR signaling and AD is supported by various observations both in human  patients58,59 and in 
mouse  models60,61. Furthermore,  p75NTR has been shown to bind Aβ12 including its oligomeric  form22 and to be 
required for the Aβ-induced death of primary hippocampal neurons both in vitro and in vivo16. Upon treatment 
Figure 6.  The inhibition of  p75NTR-mediated RhoA/ROCK signaling protects from Aβ-induced morphological 
changes. The TAT-Pep5 peptide was added to primary hippocampal cultures (DIV 14) to inhibit  p75NTR–
mediated intracellular RhoA activation and the Y-27632 inhibitor was applied to prevent ROCK activation. 
Some neuronal cultures were incubated with vehicle as control (nil). Subsequently, neuronal cultures were 
incubated with vehicle (Vehicle) or with 500 nM Aβ1–42 oligomers (Aβ1–42) for 6 h. (A) depicts representative 
dendritic segments of f-eGFP-transfected neurons treated as indicated (scale bar = 5 µm). The quantification of 
the effect of amyloid-β treatment on spine density (B), spine length (C), and spine head width (D) is shown in 
the graphs. Each column gives the mean value + SEM where the numbers indicate the analyzed neurons (N = 3). 
For statistical evaluation, a One-way ANOVA with Sidak post-test was used to compare the means of each of the 
control to the corresponding amyloid-β groups. P values as indicated or **** = p < 0.0001.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13322  | https://doi.org/10.1038/s41598-020-70153-4
www.nature.com/scientificreports/
with Aβ peptides in the µM range  p75NTR has been shown to mediate the activation of downstream signaling 
cascades involving the activation of  JNK62 and leading to cell  death12,14,16. However, whether nM concentrations 
of Aβ1–42 oligomers may activate a different intracellular cascade resulting in changes in neuronal and synaptic 
structure rather than cell death is not known. Supporting this notion is the observation that low concentrations 
of Aβ as well as sAPPα have been shown to induce neurite outgrowth in cerebellar and cortical neurons in a 
 p75NTR-dependent  manner22,63. On the other hand,  p75NTR has been shown to also function as a signal transducer 
for neurite outgrowth inhibitory  molecules64 and to negatively modulate dendritic spine density and their archi-
tecture in healthy adult hippocampal  neurons9 supporting our current observations upon Aβ treatment. However, 
intracellular signaling linking Aβ interactions with  p75NTR to dendritic spine alterations are still unknown. Here 
we show that Aβ-dependent  p75NTR signaling results in the fast activation of RhoA, triggering the activation of 
ROCK and causing an increase in the F-actin levels within individual spines. These events require  p75NTR as they 
are prevented in  p75NTR knockout neurons as well as in neurons treated with the peptide TAT-Pep5, known to act 
as a downstream signaling silencer by disrupting the recruitment of Rho-GDI to  p75NTR and thereby inhibiting 
the activation of  RhoA8. In this respect, it is noteworthy that recent studies described the involvement of the 
Figure 7.  Aβ1–42/p75NTR interactions influence actin polymerization. Individual dendritic spines are shown 
from f-eGFP transfected (green) wild type (A, C) and  p75NTR ko (B, D) neurons treated for 10 min with 500 nM 
Aβ1–42 oligomers (C, D) or vehicle (A, B). Presence of amyloid-β (red) and F-actin (phalloidin staining in grey) 
was visualized by fluorescent confocal microscopy. (C) and (D) show representative examples of dendritic 
spines with and without amyloid-β colocalization, i.e. Aβ-positive and Aβ-negative spines, respectively. A 
quantification of these results is plotted in (E), where each column represents the mean values and the error bars 
the SEM (numbers indicate the neurons used for evaluation, N = 3). A Two-way ANOVA with Tukey post-test 
was applied to determine statistical significance. **** = p < 0.0001, relevant P values are as indicated in the graph. 
Scale bars in (A) and (B) = 1 µm.
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ROCK-LIMK pathway in Aβ-induced dendritic spine  degeneration65,66. Moreover, Aβ-dependent synaptotoxicity 
in cortical neurons involves a dysregulation of the actin cytoskeleton characterized by a cofilin driven increase 
in actin  stability67.
Taken together our observations provide a strong support for a role of  p75NTR in mediating the negative effects 
of Aβ1–42 oligomers at dendritic spines and we here specifically describe a downstream signaling pathway that 
involves RhoA-ROCK activation and regulates the stability of the actin cytoskeleton within spines. Thus, our 
work contributes to a better understanding of the signaling mechanisms activated upon a treatment with Aβ1–42 
oligomers and resulting in the typical dendritic spine pathology observed in the early phases of AD and opens 
new avenues for further treatment option at the very early onset of AD.
Materials and methods
Mice. Both wild type (WT) and  p75NTRexonIV knockout  (p75NTR ko)29 mice used in this study were on the 
C57Bl/6J genetic background. All procedures concerning animals were performed in accordance with the ani-
mal welfare representative of the TU Braunschweig and were approved by the LAVES (Oldenburg, Germany, Az. 
§4 (02.05) TSchB TU BS).
cell cultures. Primary hippocampal cultures were prepared from WT or  p75NTR KO mice at embryonic day 
18 as previously  described68. Following rapid decapitation, isolated embryo brains were immediately immersed 
in Gey’s Balanced Salt Solution (GBSS) supplemented with glucose and adjusted to pH 7.3. Under a dissection 
microscope, the hippocampi were isolated in ice-cold GBSS and their dissociation was achieved by incubation 
in Trypsin–EDTA at 37 °C for 30 min followed by mechanical dissociation until a single cell suspension was 
obtained. Subsequently, the cells were re-suspended in NB + medium comprising Neurobasal medium (Gibco) 
supplemented with 2% B27 (vol/vol), 1% N2 and 0.5 mM Glutamax (Gibco) and plated at a density of 7 × 104/
cm2 on coverslips (12 mm) or at 450,000 cells/petri dishes (diameter 3 cm), previously coated with poly-L-lysine 
(Sigma). The cells were incubated at 37 °C with 99% humidity and 5%  CO2 until usage at DIV14. A medium 
change was done once a week by exchanging 20% of the medium with fresh NB + medium.
transfection. At DIV13 cultured primary hippocampal neurons were transfected using Lipofectamine 2000 
(ThermoFisher Scientific) as per manufacturer’s instructions. The following plasmids were used at a concentra-
tion of 0.8 μg/well: farnesylated-eGFP (Clonetech: pEGFP-F) alone to visualize the neurons; for overexpres-
sion studies rat  p75NTR (pcDNA3-ratp75)9 was co-expressed with farnesylated-eGFP (f-eGFP) or eGFP-tagged 
human  p75NTR was used alone (p75-eGFP)33.
Aβ peptide preparation. Soluble Aβ1–42 oligomers were prepared as previously  described69. The freeze-
dried human Aβ1–42 peptides (Bachem) were initially dissolved in sterile Milli-Q water at a stock concentration 
of 0.5 mM, sonicated in an ice-cold water bath for 10 min, and stored in small aliquots of 4.5 µl at − 70 °C until 
use. In vitro oligomerizations always were prepared fresh and 1 day prior to the start of a treatment. For this 
purpose, aliquots were thawed on ice and 3 μg of Aβ1–42 were incubated in a final volume of 20 μl sterile PBS at a 
peptide concentration of 33 µM at 4 °C for 24 h. After this, the oligomerized peptides were diluted into the cul-
ture medium (i.e., Neurobasal medium, Gibco) to obtain final treatment concentrations. For negative controls, 
equivalent amounts of PBS (i.e. vehicle) were used.
treatments. 24  h post-transfection (DIV14), the cultured hippocampal neurons were treated either 
with vehicle (PBS) or with Aβ1–42 oligomers at varying concentrations: 10 nM, 50 nM, 100 nM, 500 nM. The 
NB + medium was replaced with fresh Neurobasal medium without supplements and the peptides were diluted 
directly into the culture wells. The control wells contained no peptides but an equivalent volume of the vehicle 
used to dilute the oligomerized peptides (PBS). To interfere with  p75NTR Rho-ROCK signaling, the cell perme-
able  p75NTR inhibitor TAT-Pep5 Calbiochem (100 nM; Merck Millipore) and the p160 ROCK inhibitor Y-27632 
dihydrochloride (10 μM; Tocris Bioscience) were used to pre-treat the neurons for 15 min before the addition of 
Aβ1–42 oligomers into the same culture medium. For the analysis of dendritic spine density and morphology, the 
cultures were fixed after 15 min or 6 h. For the analysis of the F-actin content as well as for the measurement of 
RhoA activation the neurons were either fixed or lysed 10 min after Aβ1–42 oligomer addition.
Immunofluorescence. Following a 10 min fixation using cold paraformaldehyde (4% in PBS), the cells 
were incubated for 1 h at room temperature (RT) in a permeabilizing and blocking buffer containing 0.2% Tri-
ton X-100 and 1.5% Normal Goat Serum (NGS, Merck) in PBS. Next, the cells were incubated overnight at 4 °C 
on a rocker with primary antibodies diluted in the permeabilizing/blocking solution. The following primary 
antibodies were used: anti-β-Amyloid peptide (either clone BAM-10, Sigma, 1:5,000, or clone 6E10, BioLeg-
end, 1:500); mouse anti-microtubule-associated protein 2 (MAP2, 1:1,000, Sigma); rabbit anti-cleaved caspase-3 
(1:500, Millipore). Secondary antibody staining was done in the dark at room temperature for 2 h using the 
following antibodies: anti-mouse  IgGFcγ Subclass-I (1:500, Jackson ImmunoResearch Labs); anti-mouse IgG 
(H + L) Alexa-fluor 647 (1:500, Jackson ImmunoResearch Labs); anti-rabbit IgG (H + L) Cy3 (1:500, Jackson 
ImmunoResearch Labs). Finally, the cover slips were washed and mounted onto glass slides using anti-fading 
Fluoro-Gel embedding medium (Electron Microscopy Sciences). For the visualization of F-actin, some sets of 
cultures were stained with Alexa-fluor-Phalloidin 647 (ThermoFisher Scientific) diluted 1:40 in PBS following 
the incubation with the secondary antibody also in the dark for 1 h RT. To minimize actin disruption, the Triton-
permeabilization duration was reduced to 15 min. The subsequent steps remained unchanged.
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In one set of experiments, DNA fragmentation in dying neurons was detected using the Dead End fluori-
metric TUNEL system (Promega) according to the protocol provided. Briefly, after incubation with the second-
ary antibodies and washes in PBS, the coverslips were incubated in equilibration buffer for 10 min followed by 
addition of incubation buffer containing terminal deoxynucleaotidyl transferase (TdT) and fluorescein-12-dUTP 
(nucleotide mix). The coverslips were stained for 60 min at 37 °C in a humidified chamber kept in the dark. The 
reaction was then stopped using SSC buffer and the coverslips were washed in PBS, counterstained with DAPI, 
and mounted with anti-fading Fluoro-Gel embedding medium (Electron Microscopy Sciences).
RhoA G‑LiSA. The G-LISA RhoA activation assay was performed strictly according to the manufacturer’s 
instructions (G-LISA activation assay kit, Colorimetric format, Cytoskeleton Inc.). 9 × 105 cells were used for 
each treatment by pooling cells of two petri dishes (diameter: 3 cm) per treatment. After a 10-min treatment 
with vehicle or Aβ1–42 oligomers, cell lysates were prepared rapidly on ice. The lysates were clarified by centrifu-
gation at 10,000×g for 1 min at 4 °C. 30 μl of lysates were used for protein quantification and the remainder was 
snap-frozen in liquid nitrogen. This entire process was carried out under 10 min and was done sequentially for 
each test group. Protein quantification was performed by incubating the samples for 1 min at room temperature 
with the Precision Red Advanced Protein Assay Reagent (Cytoskeleton Inc.) provided by the kit. Absorbance 
readings were performed with a spectrophotometer at 600 nm. All samples were equilibrated to identical protein 
concentrations (0.5 mg/ml) and loaded in triplicates onto the plates kept on ice. The samples (in triplicates), the 
positive RhoA control (duplicate) and the buffer blank (duplicate) were incubated with an anti Rho-antibody 
and, after multiple washes, with the HRP-conjugated secondary antibody. A color reaction was done by applica-
tion of freshly prepared HRP A/B detection reagent and the wells were read for absorbance at 490 nm.
Image acquisition and analysis. Hippocampal neuronal cultures stained for MAP2 and cleaved cas-
pase-3 were imaged using a Zeiss Axioplan2 microscope equipped with  a 10 × objective (NA 0.3) and Zeiss 
AxioCam MRm camera. Different excitation wavelengths were used to image MAP2, cleaved caspase-3, and 
TUNEL in each field of view. Cleaved caspase-3 and TUNEL-positive neurons were counted manually based on 
their positivity for MAP2 in merged images created using ImageJ software (https ://image j.nih.gov/ij/).
For dendritic spine analysis, f-eGFP-labeled dendrite stretches were imaged using a confocal laser scanning 
microscope (Olympus, FluoView1000) equipped with a 40 × objective (oil, NA 1.3) with a 5 × digital zoom for a 
pixel size of 0.107 µm. Z-stack images were acquired with a 0.35 μm step-size and constant laser intensity. Well 
defined dendritic segments of healthy neurons, identified by a pyramidal cell body and by the absence of irregu-
lar membranous protrusions around the soma, were selected for imaging. Images were then deconvolved using 
AutoQuant (Media Cybernetics) and imported to the ImageJ software for analyzing dendritic spine density and 
morphology, Aβ colocalization with spines and Phalloidin fluorescence intensity.
Spine density was determined by analyzing z-stacks containing the entire dendritic stretch. The number of 
spines per unit of length (µm) was calculated by using the segmented line tool of ImageJ to measure dendritic 
length and the multipoint selection tool (ImageJ) to count spines. Morphometric analysis of dendritic spines was 
done in the same z-stacks as for the spine density using the segmented line tool of ImageJ to measure spine length 
(from its base at the dendrite to its tip) and head width (measured at the widest point of the dendritic spine).
A f-eGFP-labelled spine was considered to be colocalized with Aβ-immunoreactive puncta when seen within 
the same focal plane or one above or below. For analysis of Phalloidin intensity, regions of interest (ROIs) were 
drawn around spine heads on merged images, colocalized or not with Aβ-immunoreactivity, while being blinded 
for the phalloidin channel. Only dendritic spines with clearly defined heads were chosen for this analysis. Addi-
tional ROIs were drawn on background (no dendrite and staining). Phalloidin intensities for all selected spine 
heads were averaged and normalized to the averaged background intensity for each image individually.
All analysis were performed by an experimenter blinded for the genotype and treatment of each sample.
Data representation and statistical analysis. Data replicates generated from at least three independ-
ent experiments were used for statistical analysis. The data were collected and organized in Microsoft Excel. 
For the generation of graphs and performing the statistical tests, the values were imported into GraphPad Prism 
6. Unless otherwise mentioned, all data is reported as mean ± SEM. Student’s t-test was used to compare two 
independent groups. One-way or Two-way ANOVA multiple-comparisons followed by Sidak or Tukey post-hoc 
tests, respectively, was used for assessing significance between more than two groups. Significance was consid-
ered for p value < 0.05; plotting used the notation as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Data availability
All data generated and analyzed during this study are available from the corresponding author on reasonable 
request.
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